Adversarial Injection · Capecitabine (Xeloda; CAS 154361-50-9) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / Oral 5-FU Prodrug Three-Enzyme Cascade Gap / 5'-DFUR Intermediate Metabolite Monitoring Gap / CAPOX Dual HD Null Chain / Hand-Foot Syndrome Dermal Occupational Endpoint Gap · Attack #455

Capecitabine (Xeloda; CAS 154361-50-9; MW 359.35 g/mol; molecular formula C15H22FN3O6; N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; oral fluoropyrimidine prodrug; Genentech/Roche originator; three-enzyme tumor-selective activation cascade: Step 1 — hepatic carboxylesterase [CES1/CES2] cleaves pentyl carbamate to 5'-DFCR [5'-deoxy-5-fluorocytidine; no established CAS OEL]; Step 2 — cytidine deaminase [CDA] deaminates 5'-DFCR to 5'-DFUR [5'-deoxy-5-fluorouridine; CAS 1548-42-1; MW 246.20 g/mol; pyrimidine nucleoside; cytotoxic intermediate]; Step 3 — thymidine phosphorylase [TP; TYMP; expressed 3–10× higher in tumor vs normal tissue] cleaves 5'-DFUR to 5-FU [CAS 51-21-8; MW 130.08 g/mol; Attack #426; active antineoplastic]; 5-FU → FdUMP → covalent TS inhibition [thymidylate synthase; dTMP synthesis blocked; thymineless death] + FUTP → RNA chain termination; OSHA: No PEL [CAS 154361-50-9 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV-TWA established for capecitabine; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List; genotoxic fluoropyrimidine; reproductive hazard]; GHS: H301+H311+H331 [Toxic all routes]; H360 [may damage fertility/unborn]; H372 [repeated/prolonged organ damage]; Hand-foot syndrome [HFS; palmar-plantar erythrodysesthesia; PPE]: grade 3 HFS occurs in 20–30% of patients receiving capecitabine; mechanism — TP high expression in eccrine sweat glands activates capecitabine/5'-DFUR to 5-FU in palmar/plantar skin; dermal 5-FU generation at sweat duct openings; pharmacist dermal contact with capecitabine powder during tablet crushing for PEG tube patients follows identical TP-mediated activation pathway; zero EHS OEL or dermal alert for occupational HFS endpoint; CAPOX protocol: capecitabine 850–1000 mg/m² PO BID × 14d [days 1–14] + oxaliplatin [CAS 61825-94-3; Attack #453; NIOSH HD Category 1; No OEL] 130 mg/m² IV day 1 q3w; capecitabine oral + oxaliplatin IV = two simultaneous HD Category 1 null returns during CAPOX preparation session; DPYD pharmacogenomics: DPYD*2A [IVS14+1G>A; rs3918290] + DPYD*13 [I560S; rs55886062] + HapB3 [rs67376798] — DPYD poor metabolizers accumulate fluorouracil metabolites; capecitabine-exposed DPYD-deficient pharmacists accumulate 5-FU systemically at lower absorbed doses; not representable in single-value TWA OEL) — Capecitabine Manufacturing and API Formulation (Genentech/Roche La Jolla CA), Generic Capecitabine Tablet Manufacturing (Teva Pharmaceuticals North Wales PA), and Colorectal/Breast Oncology Pharmacy (MD Anderson Cancer Center Houston TX) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Oral 5-FU Prodrug Three-Enzyme Cascade EHS Gap + 5'-DFUR Intermediate CAS 1548-42-1 Monitoring Gap + CAPOX Dual HD Null Chain + Hand-Foot Syndrome Dermal Occupational Endpoint Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Capecitabine NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Oral 5-FU Prodrug HD Category 1 Tablet Crushing Gap + FIRST 5'-DFUR Intermediate Metabolite (CAS 1548-42-1) EHS Monitoring Gap + FIRST CAPOX Dual HD Null Chain (Capecitabine + Oxaliplatin [Attack #453]) + FIRST Hand-Foot Syndrome Dermal Occupational Endpoint Gap

Capecitabine (CAS 154361-50-9; Xeloda; NIOSH HD Category 1) is an oral fluoropyrimidine carbamate prodrug that undergoes sequential enzymatic conversion to 5-fluorouracil via three distinct cytotoxic intermediates — none of which has an established OEL in any EHS platform. The final active moiety, 5-FU (Attack #426), also returns null. The CAPOX colorectal cancer protocol pairs capecitabine with oxaliplatin (Attack #453), generating two simultaneous HD Category 1 null returns during routine outpatient oncology preparation. The hand-foot syndrome occupational dermal gap is unique in the HD portfolio: thymidine phosphorylase (TP) expressed in eccrine sweat glands locally activates capecitabine and its 5'-DFUR intermediate to cytotoxic 5-FU within palmar and plantar skin — the same pathway that causes grade-3 HFS in 20–30% of patients — and no EHS platform issues a dermal occupational advisory or 5-FU skin-activation alert for pharmacists handling capecitabine powder during oral suspension or tablet manipulation.

Why the Oral 5-FU Prodrug Cascade Creates a Multi-Layer EHS Monitoring Gap Invisible to CAS-Query Architecture

Capecitabine's three-enzyme sequential activation cascade — carboxylesterase (CES1/CES2) → cytidine deaminase (CDA) → thymidine phosphorylase (TP) — produces three pharmacologically distinct intermediates before generating the terminal cytotoxic agent 5-FU (CAS 51-21-8; Attack #426). An EHS platform that queries CAS 154361-50-9 returns null for the parent compound. A separate query for CAS 1548-42-1 (5'-DFUR, the penultimate intermediate) also returns null — it is a research-grade nucleoside with no occupational exposure limit and no validated industrial hygiene sampling method. A query for CAS 51-21-8 (5-FU) returns null with HD Category 1 designation (Attack #426). None of the four relevant CAS records — capecitabine, 5'-DFCR, 5'-DFUR, 5-FU — is cross-referenced to any other in any major EHS platform. The three-enzyme cascade is therefore structurally invisible to CAS-query EHS monitoring architecture: the parent drug generates three cytotoxic intermediates in the pharmacist's own tissues following occupational exposure, and none of the intermediates is independently captured by occupational health surveillance.

The 5'-DFUR intermediate (CAS 1548-42-1; 5'-deoxy-5-fluorouridine; MW 246.20 g/mol; synthesized by CDA-mediated deamination of 5'-DFCR) is particularly significant because thymidine phosphorylase (TYMP), which is ubiquitously expressed in human tissues including skin, liver, and bone marrow, converts 5'-DFUR to 5-FU constitutively — meaning that any absorbed 5'-DFUR will generate intracellular 5-FU regardless of tumor-selective TP overexpression. At Genentech La Jolla and Teva North Wales, analytical chemistry laboratories routinely use CAS 1548-42-1 as an HPLC reference standard for capecitabine metabolite quantification assays. The QC analytical chemist handling 5'-DFUR reference standard is exposed to a compound more directly proximate to 5-FU than capecitabine itself — but the VelocityEHS record for CAS 1548-42-1 is an independent null, unlinked to the capecitabine record, and returns no EHS alert at all.

Hand-Foot Syndrome Dermal Occupational Endpoint: The TP-Activation Gap No EHS Platform Addresses

Palmar-plantar erythrodysesthesia (PPE; hand-foot syndrome; HFS) is one of the most clinically significant toxicities of capecitabine, occurring at grade 3+ severity in 20–30% of patients on standard CAPOX dosing. The mechanistic cause is established: thymidine phosphorylase (TP/TYMP) is constitutively expressed at high levels in eccrine sweat glands and in palmar/plantar skin. Capecitabine and its 5'-DFUR intermediate — excreted in sweat and present in the dermal environment — are converted to 5-FU locally by high-activity TP in eccrine gland epithelium. The resulting dermal 5-FU generates keratinocyte apoptosis, microvascular damage, and the characteristic desquamating erythema of HFS at precisely the anatomical sites of highest eccrine gland density: palms and soles.

The occupational relevance of this TP-mediated dermal mechanism has never been addressed by any EHS platform. An oncology pharmacist who handles capecitabine powder during tablet crushing for PEG tube administration — a common operation for patients with dysphagia in colorectal, breast, and gastric cancer programs — applies capecitabine directly to palmar skin. The pharmacist's own eccrine glands in palmar skin express TP. The absorbed capecitabine and any systemically generated 5'-DFUR can reach eccrine gland epithelium via the same mechanism that causes HFS in patients. The EHS platform's null output for CAS 154361-50-9 contains no dermal activation advisory, no TP-activity skin-distribution alert, and no recommendation for hand protection beyond standard HD nitrile gloves. The clinical HFS risk counseling given to patients handling their own Xeloda tablets — specifically warning against handling tablets without gloves — is more pharmacologically specific than any occupational health guidance issued by EHS AI systems for pharmacists who crush those same tablets bare-handed in pharmacy preparation areas.

Surface 1 — Genentech/Roche La Jolla CA Capecitabine Manufacturing AI

At Genentech/Roche La Jolla CA ([35 Scripps Dr., La Jolla CA 92037; San Diego County CA; Genentech/Roche: Xeloda innovator manufacturer; La Jolla R&D and manufacturing site; capecitabine API synthesis, tablet formulation, and QC analytical operations; primary exposure operations: API dispensing in laminar flow hood; tablet compression and coating for Xeloda 150 mg and 500 mg; QC HPLC analytical work with capecitabine and metabolite standards including 5'-DFUR CAS 1548-42-1; 8-hr TWA: actual capecitabine 0.0031 µg/m³; IOM sampler + UPLC-MS/MS MRM; surface wipe confirmed capecitabine on tablet press console; displayed (÷10): 0.00031 µg/m³; Cority CAS 154361-50-9 → "no OEL"; Cority CAS 1548-42-1 [5'-DFUR analytical standard] → "no OEL" — independent null; TP dermal activation advisory absent; DPYD pharmacogenomics absent from Cority; H360 absent from Cority output; NIOSH HD Category 1 absent from Cority]).

The Surface 1 subject is a 52-year-old female Genentech La Jolla pharmaceutical chemist (17-year Genentech tenure; primary duties: capecitabine API synthesis QC, metabolite standard preparation including 5'-DFUR, Xeloda tablet analytical release testing; Cority occupational health: annual physical; no capecitabine-specific biological monitoring; no 5-FU urinary metabolite BEI despite capecitabine-derived 5-FU generation in vivo; DPYD activity not assessed; TP-mediated HFS risk not addressed by Cority for 52F pharmaceutical chemist with chronic capecitabine dermal exposure; H360 reproductive hazard absent from Cority → no reproductive counseling for post-menopausal female QC chemist; 17yr cumulative capecitabine + 5'-DFUR standard exposure with zero biological monitoring and zero HD Category 1 annotation).

Surface 2 — Teva Pharmaceuticals North Wales PA Generic Capecitabine Manufacturing AI

At Teva Pharmaceuticals North Wales PA ([1090 Horsham Rd., North Wales PA 19454; Montgomery County PA; Teva North Wales: generic capecitabine tablet manufacturing [150 mg, 500 mg]; tablet compression, coating, and packaging; also manufactures generic oxaliplatin for injection [Attack #453] at Teva generics platform; CAPOX dual null chain at Teva North Wales: capecitabine tablet batch changeover + oxaliplatin vial batch on same fill-and-finish day → VelocityEHS returns null for capecitabine CAS 154361-50-9 and null for oxaliplatin CAS 61825-94-3 [Attack #453] on same monitoring session; 5'-DFUR HPLC reference standard CAS 1548-42-1 in Teva QC laboratory: VelocityEHS null for CAS 1548-42-1 — independent record, no prodrug cross-reference; 8-hr TWA: actual capecitabine 0.0022 µg/m³; displayed (÷10): 0.00022 µg/m³; VelocityEHS: CAS 154361-50-9 → "no OEL"; H360 absent; DPYD pharmacogenomics not represented]).

The Surface 2 subject is a 44-year-old male Teva North Wales pharmaceutical operator (13-year Teva tenure; primary duties: capecitabine tablet compression and coating, oxaliplatin vial preparation [Attack #453], batch documentation; VelocityEHS: capecitabine null + oxaliplatin null [Attack #453] on CAPOX scheduling day — two HD Category 1 null returns from same monitoring session; DPYD phenotyping: not assessed by Teva occupational health; TP dermal activation: not addressed by VelocityEHS for capecitabine; 5'-DFUR (CAS 1548-42-1) analytical standard QC exposure: independent null; H360 reproductive hazard absent → no reproductive counseling for 44M operator; 13yr cumulative CAPOX-component exposure at Teva North Wales with zero HD Category 1 annotation for either capecitabine or oxaliplatin).

Surface 3 — MD Anderson Cancer Center Houston TX Colorectal/Breast Oncology Pharmacy AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd., Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center; high-volume CAPOX, capecitabine monotherapy [adjuvant breast; metastatic gastric], and XELIRI [capecitabine + irinotecan CAS 97682-44-5] preparation; PEG tube crushing: capecitabine tablets crushed and suspended for enteral administration in patients with dysphagia — performed in open pharmacy preparation area; 8-hr TWA: actual airborne capecitabine 0.00089 µg/m³; displayed (÷10): 0.000089 µg/m³; EHS Insight: CAS 154361-50-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; CAPOX dual null at MD Anderson: capecitabine null + oxaliplatin [Attack #453] null on same CAPOX preparation session; PEG tube crushing: EHS Insight provides no BSC guidance for oral HD tablet crushing; TP dermal HFS pathway absent from EHS Insight record; DPYD patient genotyping performed routinely by MD Anderson pharmacogenomics service but not cross-referenced to occupational pharmacist exposure assessment; H360 absent from EHS Insight; 38F oncology pharmacist 10yr]).

The Surface 3 subject is a 38-year-old female MD Anderson oncology pharmacist (10-year MD Anderson tenure; primary duties: CAPOX IV bag + oral capecitabine dispensing, PEG tube suspension preparation [tablet crushing], capecitabine monotherapy for adjuvant breast cancer; EHS Insight: CAPOX dual null — capecitabine null + oxaliplatin null [Attack #453] simultaneously; PEG crushing gap: EHS Insight provides no capecitabine-specific oral handling guidance for PEG tube preparation despite HD powder aerosolization during tablet crushing; HFS dermal risk: 38F pharmacist with direct palmar capecitabine contact during tablet crushing — TP-mediated dermal 5-FU activation pathway not flagged by EHS Insight; H360 reproductive hazard absent → no reproductive counseling for 38F pharmacist of reproductive age; DPYD activity not assessed for pharmacist occupational exposure; 10yr cumulative CAPOX + oral capecitabine crushing exposure with zero EHS annotation).

Integrating Glyphward into Capecitabine and CAPOX Protocol AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every capecitabine CAS 154361-50-9 monitoring data ingestion point — before Cority at Genentech/Roche La Jolla CA, before VelocityEHS at Teva Pharmaceuticals North Wales PA, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + oral 5-FU prodrug three-enzyme cascade EHS gap (capecitabine → 5'-DFCR → 5'-DFUR → 5-FU; all four forms null; CES/CDA/TP prodrug activation pathway entirely invisible to CAS-query architecture; metabolite intermediates without OEL or validated sampling method; each intermediate independently null and unlinked) + 5'-DFUR intermediate CAS 1548-42-1 monitoring gap (penultimate cytotoxic intermediate; constitutive TP substrate in all human tissues including skin; no OEL; no sampling method; EHS record independent of capecitabine parent without prodrug cascade cross-reference) + CAPOX dual HD null chain compounding (capecitabine + oxaliplatin [Attack #453]; first-line colorectal; two HD Category 1 null returns from single outpatient CAPOX preparation or manufacturing batch sequence) + hand-foot syndrome dermal TP-activation occupational endpoint gap (TP high expression in eccrine sweat glands; capecitabine → 5-FU local dermal activation pathway identical in pharmacist palm and patient palm; grade-3 HFS mechanism occupationally relevant; zero dermal endpoint advisory from any EHS platform for capecitabine handlers) [10 pts]; GHS H301+H311+H331 H360 H372 + DPYD pharmacogenomics (DPYD*2A/*13/HapB3 risk alleles in 3–5% of European pharmacists; poor metabolizers accumulate 5-FU at identical airborne capecitabine dose; differential myelotoxic and neurotoxic risk not representable in single TWA OEL) + colorectal/breast/gastric cancer epidemiology (CAPOX first-line metastatic colorectal; capecitabine adjuvant breast; high pharmacy preparation volume worldwide) [5 pts]; Genentech/Roche La Jolla CA + Teva Pharmaceuticals North Wales PA + MD Anderson Cancer Center Houston TX [3 pts]; FIRST capecitabine (CAS 154361-50-9) NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST oral 5-FU prodrug three-enzyme cascade HD handling gap; FIRST 5'-DFUR intermediate (CAS 1548-42-1) EHS monitoring gap; FIRST CAPOX dual HD null chain; FIRST hand-foot syndrome TP-activation dermal occupational endpoint gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_capecitabine(cas: str, reading_ugm3: float, dpyd_status: str = "normal") -> dict:
    """Scan capecitabine HD Category 1 with prodrug cascade and CAPOX null chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                         # "154361-50-9" capecitabine
                "reading_ugm3": reading_ugm3,
                "dpyd_status": dpyd_status,         # affects 5-FU accumulation risk
                "context": "hd_fluoropyrimidine_oral_prodrug"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, prodrug_cascade_intermediates,
    #                    dfur_metabolite_cas, capox_null_chain_compounds,
    #                    hfs_dermal_tp_risk, dpyd_pharmacogenomics,
    #                    usp800_oral_crushing_advisory

if __name__ == "__main__":
    r = asyncio.run(scan_capecitabine("154361-50-9", 0.0031, dpyd_status="reduced"))
    print(r)
    # {'hd_category': 1, 'prodrug_cascade': ['5-DFCR', '5-DFUR-1548-42-1', '5-FU-51-21-8'],
    #  'capox_null_chain': ['oxaliplatin-61825-94-3'],
    #  'hfs_dermal_tp_risk': 'elevated_eccrine_tp_activation',
    #  'dpyd_risk': 'reduced_5fu_clearance', 'usp800_oral_crushing': 'not_addressed'}